Trial Profile
Pilot study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2019
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 18 Nov 2019 Status changed from recruiting to completed.
- 27 May 2016 New trial record